272 related articles for article (PubMed ID: 32642869)
1. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
Sievers P; Hielscher T; Schrimpf D; Stichel D; Reuss DE; Berghoff AS; Neidert MC; Wirsching HG; Mawrin C; Ketter R; Paulus W; Reifenberger G; Lamszus K; Westphal M; Etminan N; Ratliff M; Herold-Mende C; Pfister SM; Jones DTW; Weller M; Harter PN; Wick W; Preusser M; von Deimling A; Sahm F
Acta Neuropathol; 2020 Sep; 140(3):409-413. PubMed ID: 32642869
[No Abstract] [Full Text] [Related]
2. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.
Tang V; Lu R; Mirchia K; Van Ziffle J; Devine P; Lee J; Phillips JJ; Perry A; Raleigh DR; Lucas CG; Solomon DA
Acta Neuropathol; 2023 Apr; 145(4):497-500. PubMed ID: 36723772
[No Abstract] [Full Text] [Related]
3. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
Wang JZ; Patil V; Liu J; Dogan H; Tabatabai G; Yefet LS; Behling F; Hoffman E; Bunda S; Yakubov R; Kaloti R; Brandner S; Gao A; Cohen-Gadol A; Barnholtz-Sloan J; Skardelly M; Tatagiba M; Raleigh DR; Sahm F; Boutros PC; Aldape K; ; Nassiri F; Zadeh G
Acta Neuropathol; 2023 Jul; 146(1):145-162. PubMed ID: 37093270
[TBL] [Abstract][Full Text] [Related]
4. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
[TBL] [Abstract][Full Text] [Related]
5. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
[No Abstract] [Full Text] [Related]
6. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
7. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
Guyot A; Duchesne M; Robert S; Lia AS; Derouault P; Scaon E; Lemnos L; Salle H; Durand K; Labrousse F
J Neurooncol; 2019 Dec; 145(3):449-459. PubMed ID: 31729637
[TBL] [Abstract][Full Text] [Related]
9. Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.
Khan AB; English CW; Chen WC; Athukuri P; Bayley JC; Brandt VL; Shetty A; Hadley CC; Choudhury A; Lu HC; Harmanci AO; Harmanci AS; Magill ST; Raleigh DR; Klisch TJ; Patel AJ
Acta Neuropathol; 2023 Apr; 145(4):501-503. PubMed ID: 36729132
[No Abstract] [Full Text] [Related]
10. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
[TBL] [Abstract][Full Text] [Related]
11. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
Simon M; Park TW; Köster G; Mahlberg R; Hackenbroch M; Boström J; Löning T; Schramm J
J Neurooncol; 2001 Dec; 55(3):149-58. PubMed ID: 11859969
[TBL] [Abstract][Full Text] [Related]
12. P16 deletion and mutation analysis in human brain tumors.
Barker FG; Chen P; Furman F; Aldape KD; Edwards MS; Israel MA
J Neurooncol; 1997 Jan; 31(1-2):17-23. PubMed ID: 9049826
[TBL] [Abstract][Full Text] [Related]
13. Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas.
Ono Y; Ueki K; Joseph JT; Louis DN
Acta Neuropathol; 1996; 91(3):221-5. PubMed ID: 8834533
[TBL] [Abstract][Full Text] [Related]
14. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
[TBL] [Abstract][Full Text] [Related]
15. N-ethyl-N-nitrosourea (ENU)-induced meningiomatosis and meningioma in p16(INK4a)/p19(ARF) tumor suppressor gene-deficient mice.
Morrison JP; Satoh H; Foley J; Horton JL; Dunnick JK; Kissling GE; Malarkey DE
Toxicol Pathol; 2007 Oct; 35(6):780-7. PubMed ID: 17943659
[TBL] [Abstract][Full Text] [Related]
16. Assessment of CDKN2A/B homozygous deletion in gliomas: To FISH or not to FISH?
Broggi G; Barresi V
J Neuropathol Exp Neurol; 2023 Jul; 82(8):742-744. PubMed ID: 37308327
[No Abstract] [Full Text] [Related]
17. Loss of p16
Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
[TBL] [Abstract][Full Text] [Related]
18. [Methylation and expression analysis of p16(INK4a) and RB genes in meningiomas].
Chen MN; Mao Q; Liu YH; Mao BY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Jun; 21(3):277-9. PubMed ID: 15192837
[TBL] [Abstract][Full Text] [Related]
19. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas.
Vij M; Cho BB; Yokoda RT; Rashidipour O; Umphlett M; Richardson TE; Tsankova NM
Acta Neuropathol Commun; 2023 May; 11(1):73. PubMed ID: 37138345
[TBL] [Abstract][Full Text] [Related]
20. Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas.
Leuraud P; Marie Y; Robin E; Huguet S; He J; Mokhtari K; Cornu P; Hoang-Xuan K; Sanson M
J Neurooncol; 2000 Dec; 50(3):207-13. PubMed ID: 11263500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
